Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zhi-Cheng Gong is active.

Publication


Featured researches published by Zhi-Cheng Gong.


Food Chemistry | 2013

Preparative isolation and purification of seven main antioxidants from Eucommia ulmoides Oliv. (Du-zhong) leaves using HSCCC guided by DPPH-HPLC experiment

Xing-Ping Dai; Qiong Huang; Bo-Ting Zhou; Zhi-Cheng Gong; Zhao-Qian Liu; Shuyun Shi

Seven antioxidants were purified from Eucommia ulmoides Oliv. leaves using HSCCC guided by DPPH-HPLC experiment. HSCCC was successfully used to separate target antioxidants by three runs with different solvent systems after D101 column chromatography fractionation. Ethyl acetate-n-butanol-water (1:2:3, v/v/v) was selected as the optimum solvent system to purify geniposidic acid. Ethyl acetate-ethanol-water (4:1:5, v/v/v) was used to isolate caffeic acid, chlorogenic acid and ferulic acid. While three flavonoids, quercetin-3-O-sambubioside, rutin and isoquercitrin were purified by petroleum ether-ethyl acetate-methanol-water (1:5:1:5, v/v/v/v). The structures were identified by MS and NMR. Antioxidant activities were assessed, and compounds 2-7 showed strong antioxidant activities. This is the first report about separation of antioxidants from E. ulmoides leaves by HSCCC. The results indicated that the combinative methods using DPPH-HPLC and HSCCC could be widely applied for screening and isolation of antioxidants from complex extracts.


British Journal of Clinical Pharmacology | 2008

The association of adiponectin allele 45T/G and −11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients

Hong Sun; Zhi-Cheng Gong; Ji-Ye Yin; Hai-Ling Liu; Ying-Zi Liu; Zhi-Wei Guo; Hong-Hao Zhou; Jing Wu; Zhao-Qian Liu

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Rosiglitazone is able to increase serum adiponectin levels significantly in Type 2 diabetic patients. :The role of genetic factors that determine the marked interindividual variability in glucose-lowering efficacy of rosiglitazone in Chinese patients is not known. The current study was designed to evaluate the impact of the adiponectin common allele 45T/G and -11377C/G polymorphisms on the response to rosiglitazone monotherapy in Chinese patients with Type 2 diabetes (T2D). WHAT THIS STUDY ADDS The genetic polymorphisms of adiponectin alleles 45T/G and -11377C/G as well as their common diplotypes are significantly associated with an attenuated fasting plasma glucose, postprandial plasma glucose and homeostasis model assessment for insulin resistance as well as an enhanced adiponectin concentration in Chinese patients with T2D after rosiglitazone treatment. AIMS The aim of the present study was to evaluate the impact of adiponectin allele T45G and C-11377G genetic polymorphisms on efficacy of rosiglitazone in Chinese patients with type 2 diabetes (T2D). METHODS Patients with T2D (n = 255) and 120 healthy volunteers were enrolled to identify 45T/G and -11377C/G genotypes by polymerase chain reaction-restriction fragment length polymorphism assay. Forty-two T2D patients with different 45T/G or -11377C/G genotypes received orally rosiglitazone as a single-dose therapy (4 mg day-1 p.o.) for 12 weeks. Serum triglyceride, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin, fasting serum insulin, postprandial serum insulin, total cholesterol, homeostasis model assessment for insulin resistance (HOMA-IR), low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol (HDL-c) and adiponectin concentration were determined before and after rosiglitazone treatment. RESULTS We showed an attenuated rosiglitazone effect in patients with -11377CG+GG heterozygote genotype on FPG, PPG, HOMA-IR compared with -11377CC homozygote genotype. However, we found an enhanced rosiglitazone effect on serum adiponectin concentration in patients with -11377CC homozygote genotype compared with -11377CG+GG heterozygote genotype (P = 0.000) and in patients with 45TG + GG heterozygote genotype compared with 45TT homozygote genotype (P = 0.018). Finally, our results showed that there was an enhanced effect in patients with -11377/45 CGTT diplotype compared with other discovered diplotypes on FPG (P = 0.001) and PPG (P = 0.003) after rosiglitazone treatment. CONCLUSIONS These data suggest that the adiponectin allele 45T/G and -11377C/G polymorphisms are significantly associated with the therapeutic efficacy of multiple-dose rosiglitazone in Chinese patients with T2D.


Clinical Pharmacology & Therapeutics | 2010

KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) Polymorphisms Affect Therapeutic Efficacy of Repaglinide in Chinese Patients With Type 2 Diabetes

Min Yu; Xiao-Jing Xu; Ji-Ye Yin; Jing Wu; Xing Chen; Zhi-Cheng Gong; H.-Y. Ren; Qiong Huang; F.-F. Sheng; Hong-Hao Zhou; Z.-Q. Liu

This study showed that the polymorphisms KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) are associated with a heightened risk of developing type 2 diabetes mellitus (T2DM). We also explored the effects of these polymorphisms on the efficacy of repaglinide therapy in Chinese patients with T2DM. A total of 259 patients with T2DM and 188 healthy controls were genotyped. Forty patients with various genotypes were randomly selected to undergo an 8‐week repaglinide treatment regimen. Patients with the G allele of the KCNJ11 Lys23Glu polymorphism showed higher levels of fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) (P < 0.05). After repaglinide treatment, patients with the GA or AA genotype showed higher levels of FPG, PPG, and glycated hemoglobin (HbA1c) compared with patients with the GG genotype (P < 0.05). Patients with the C allele of TCF7L2 rs290487(C/T) had higher total cholesterol levels and lower body mass index (BMI) (P < 0.05). In patients with the TT genotype, the drug showed better efficacy with respect to levels of fasting insulin, triglycerides, and low‐density lipoprotein cholesterol (LDL‐c) than in patients with the CC or CT genotype (P < 0.05). The KCNJ11 and TCF7L2 polymorphisms were associated with repaglinide efficacy.


Tumor Biology | 2016

AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis

Zhaoyang Zeng; H. Bo; Zhi-Cheng Gong; Yu Lian; XiaYu Y. Li; Wenling Zhang; Hongyu Deng; Mei-juan Zhou; Shuping Peng; Guiyuan Li; Wei Xiong

Long noncoding RNAs (lncRNAs) have emerged as a major regulator of cancer. Significant fraction of lncRNAs is represented on widely used microarray platforms; however, many of which have no known function. To discover novel lung cancer-related lncRNAs, we analyzed the lncRNA expression patterns in five sets of previously published lung cancer gene expression profile data that were represented on Affymetrix HG-U133 Plus 2.0 array, and identified dysregulated lncRNAs in lung cancer. One lncRNA, actin filament associated protein 1 antisense RNA1 (AFAP1-AS1), was the most significantly upregulated in lung cancer and associated with poor prognosis. In vitro experiments demonstrated that AFAP1-AS1 knockdown significantly inhibited the cell invasive and migration capability in lung cancer cells. AFAP1-AS1 knockdown also increased the expression of its antisense protein coding gene, actin filament associated protein 1 (AFAP1), and affected the expression levels of several small GTPase family members and molecules in the actin cytokeratin signaling pathway, which suggested that AFAP1-AS1 promoted cancer cell metastasis via regulation of actin filament integrity. Our findings extend the number of noncoding RNAs functionally implicated in lung cancer progression and highlight the role of AFAP1-AS1 as potential prognostic biomarker and therapeutic target of lung cancer.


Clinical and Experimental Pharmacology and Physiology | 2012

KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients

Xing-Ping Dai; Qiong Huang; Ji-Ye Yin; Yu Guo; Zhi-Cheng Gong; Minxiang Lei; Tiejian Jiang; Hong-Hao Zhou; Zhao-Qian Liu

The present study evaluated the effects of KCNQ1 rs2237892 and rs2237895 polymorphisms on repaglinide efficacy in Chinese patients with Type 2 diabetes mellitus (T2DM). In all, 367 T2DM patients and 214 controls were genotyped. Forty of the T2DM patients were randomly selected to undergo 8 weeks repaglinide treatment. The frequency of the rs2237892 allele was lower in the T2DM patients than in the control group (P < 0.05). The frequency of the rs2237895 C allele was higher in T2DM patients than in healthy control subjects (P < 0.05). Diabetic patients with the rs2237892 risk C allele had lower fasting insulin levels (P < 0.01) and homeostasis model assessment of insulin resistance (HOMA‐IR; P < 0.01) values than carriers of the T allele. Diabetic patients with the rs2237895 risk C allele had higher fasting plasma glucose (P < 0.01), postprandial plasma glucose (PPG) levels (P < 0.01) and HOMA‐IR values (P < 0.01) than those with the A allele. Following repaglinide treatment, those T2DM patients with the rs2237892 T allele and rs2237895 C allele were more likely to have a positive response to repaglinide in terms of PPG levels (P < 0.05) than T2DM patients with the rs2237892 CC and rs2237895 AA genotypes. In conclusion, KCNQ1 rs2237892 and rs2237895 polymorphisms were found to be associated with the therapeutic efficacy of repaglinide in Chinese T2DM patients.


British Journal of Clinical Pharmacology | 2012

NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes

Zhi-Cheng Gong; Qiong Huang; Xing-Ping Dai; Guang-Hua Lei; Hong-Bin Lu; Ji-Ye Yin; Xiao-Jing Xu; Jian Qu; Qi Pei; Min Dong; Bo-Ting Zhou; Jie Shen; Gan Zhou; Hong-Hao Zhou; Zhao-Qian Liu

AIMS We aimed to determine whether NeuroD1/BETA2 and PAX4 polymorphisms were associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetes mellitus (T2DM) patients. METHODS Three hundred and sixty-eight T2DM patients and 132 healthy control subjects were genotyped by restriction fragment length polymorphism. Forty-three patients with various genotypes were randomly selected to undergo 8 weeks of repaglinide treatment (3 mg day(-1)). Fasting plasma glucose, postprandial plasma glucose, glycated haemoglobin, fasting and postprandial serum insulin (FINS, PINS), homeostasis model assessment for insulin resistance, serum triglyceride, total cholesterol, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol were determined before and after repaglinide treatment. RESULTS The allelic frequency of NeuroD1/BETA2 T45 was higher in T2DM patients than in the control subjects [13.45 vs. 6.82%, P < 0.01, odds ratios = 2.342 (1.365, 4.019), P= 0.002]. Type 2 diabetes mellitus patients with the mutated allele of NeuroD1/BETA2 A45T polymorphism showed higher FINS (13.46 ± 12.57 vs. 10.04 ± 7.09 mU l(-1) , P < 0.05) (11.67, 14.83 vs. 8.38, 11.37) and PINS (52.11 ± 40.93 vs. 68.66 ± 43.87 mU l(-1), P < 0.05) (44.89, 58.35 vs. 55.35, 88.87) than individuals with the T allele. The PAX4 R121W R allele carriers had higher PINS (52.11 ± 40.93 vs. 68.66 ± 43.87 mU l(-1), P < 0.05) (44.89, 58.35 vs. 55.35, 88.87) than subjects with the W allele. After repaglinide treatment, patients with the T allele of NeuroD1/BETA2 A45T polymorphisms had attenuated efficacy on fasting plasma glucose (-2.79 ± 2.14 vs.-0.99 ± 1.80 mmol l(-1), P < 0.01) (-3.53, -1.84 vs.-1.99, -0.13) and postprandial plasma glucose (-6.71 ± 5.90 vs.-2.54 ± 3.39 mmol l(-1), P < 0.01) (-9.28, -4.62 vs.-4.34, -0.84). Patients with the RR genotype of PAX4 R121W showed better efficacy with respect to the level of postprandial plasma glucose than R/W genotypes (-6.53 ± 6.52 vs.-2.95 ± 1.17 mmol l(-1), P < 0.05) (-8.20, -4.89 vs.-3.92, -1.20). CONCLUSIONS The NeuroD1/BETA2 and PAX4 polymorphisms were substantially associated with plasma glucose level after repaglinide monotherapy.


Clinica Chimica Acta | 2009

Evidence for an effect of clozapine on the regulation of fat-cell derived factors

Zhi Yang; Ji-Ye Yin; Zhi-Cheng Gong; Qiong Huang; Hao Chen; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu

OBJECTIVES The aims of this study were to investigate the effects of clozapine on adipocyte differentiation and its regulation for fat-cell derived factors. MATERIALS AND METHODS 3T3-L1 preadipocytes were induced into differentiated adipocytes by the addition of 5 microg/ml of insulin, 1 micromol/l dexamethasone, 10 mmol/l IBMX, 1% DMSO, and 10% FBS in DMEM medium. The semi-quantitative RT-PCR was performed to determine the mRNA levels of PPAR gamma, C/EBP alpha, ADD1/SREBP(1C), LPL, and DGAT1. The expression levels of LPL and DGAT1 proteins in the adipocytes treated with clozapine or rosiglitazone were determined by Western blot analysis. The triglyceride concentration was determined by use of GPO-POD assay Kit. RESULTS Clozapine enhanced the expression level of ADD1/SREBP(1C) mRNA and triglyceride concentration in the differentiated adipocytes. Clozapine significantly suppressed the expression levels of LPL mRNA and LPL protein with a dose-dependent and time-dependent manner, respectively. CONCLUSION These data suggest that clozapine might play an important role in inducing adipocyte differentiation and the regulation of fat-cell derived factors.


Clinical and Experimental Pharmacology and Physiology | 2011

Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.

Min Dong; Zhi-Cheng Gong; Xing-Ping Dai; Guang-Hua Lei; Hong-Bin Lu; Jian Qu; Hong-Hao Zhou; Zhao-Qian Liu

1. The aim of this study was to investigate the association of the serine racemase (SRR) rs391300 G/A polymorphism with the risk of diabetes mellitus type 2 (T2DM) and to assess the impacts of the polymorphism on the therapeutic efficacy of metformin in Chinese patients.


Journal of Chromatography A | 2017

Hollow porous ionic liquids composite polymers based solid phase extraction coupled online with high performance liquid chromatography for selective analysis of hydrophilic hydroxybenzoic acids from complex samples

Xing-Ping Dai; Dongsheng Wang; Hui Li; Yanyi Chen; Zhi-Cheng Gong; Haiyan Xiang; Shuyun Shi; Xiaoqing Chen

Polar and hydrophilic properties of hydroxybenzoic acids usually made them coelute with interferences in high performance liquid chromatography (HPLC) analysis. Then selective analysis of them was necessary. Herein, hollow porous ionic liquids composite polymers (PILs) based solid phase extraction (SPE) was firstly fabricated and coupled online with HPLC for selective analysis of hydroxybenzoic acids from complex matrices. Hollow porous PILs were firstly synthesized using Mobil Composition of Matter No. 48 (MCM-48) spheres as sacrificial support, 1-vinyl-3-methylimidazolium chloride (VMIM+Cl-) as monomer, and ethylene glycol dimethacrylate (EGDMA) as cross-linker. Various parameters affecting synthesis, adsorption and desorption behaviors were investigated and optimized. Steady-state adsorption studies showed the resulting hollow porous PILs exhibited high adsorption capacity, fast adsorption kinetics, and excellent specific adsorption. Subsequently, the application of online SPE system was studied by selective analysis of protocatechuic acid (PCA), 4-hydroxybenzoic acid (4-HBA), and vanillic acid (VA) from Pollen Typha angustifolia. The obtained limit of detection (LOD) varied from 0.002 to 0.01μg/mL, the linear range (0.05-5.0μg/mL) was wide with correlation coefficient (R) from 0.9982 to 0.9994, and the average recoveries at three spiking levels ranged from 82.7 to 102.4%, with column-to-column relative standard deviation (RSD) below 8.1%. The proposed online method showed good accuracy, precision, specificity and convenience, which opened up a universal and efficient route for selective analysis of hydroxybenzoic acids from complex samples.


CNS Neuroscience & Therapeutics | 2014

Novel Susceptibility Loci were Found in Chinese Genetic Generalized Epileptic Patients by Genome-wide Association Study

Ying Zhang; Jian Qu; Chen-Xue Mao; Zhi-Bin Wang; Xiao-Yuan Mao; Bo-Ting Zhou; Ji-Ye Yin; Hong-Yu Long; Bo Xiao; Zhi-Cheng Gong; Yu Zhang; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu

Correspondence Professor Zhao-Qian Liu, Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. Tel.: +86 731 84805380; Fax: +86 731 82354476; E-mail: [email protected] Received 31 July 2014; revision 19 August 2014; accepted 22 August 2014

Collaboration


Dive into the Zhi-Cheng Gong's collaboration.

Top Co-Authors

Avatar

Zhao-Qian Liu

Central South University

View shared research outputs
Top Co-Authors

Avatar

Hong-Hao Zhou

Central South University

View shared research outputs
Top Co-Authors

Avatar

Ji-Ye Yin

Central South University

View shared research outputs
Top Co-Authors

Avatar

Xing-Ping Dai

Central South University

View shared research outputs
Top Co-Authors

Avatar

Qiong Huang

Central South University

View shared research outputs
Top Co-Authors

Avatar

Bo-Ting Zhou

Central South University

View shared research outputs
Top Co-Authors

Avatar

Jian Qu

Central South University

View shared research outputs
Top Co-Authors

Avatar

Jing Wu

Central South University

View shared research outputs
Top Co-Authors

Avatar

Min Dong

Central South University

View shared research outputs
Top Co-Authors

Avatar

Xiang-Ping Li

Central South University

View shared research outputs
Researchain Logo
Decentralizing Knowledge